EcoDrugPlus

Toll Like Receptor 7

Ensembl ID : ENSOKIG00005007816
Gene Symbol: TLR7
3 Cross references
197 Possible Orthologues:

Toll Like Receptor 8

Ensembl ID : ENSOKIG00005043622
Gene Symbol: TLR8
3 Cross references
130 Possible Orthologues:

Toll Like Receptor 8

Ensembl ID : ENSOKIG00005007808
Gene Symbol: TLR8
3 Cross references
174 Possible Orthologues:

Toll Like Receptor 8

Ensembl ID : ENSOKIG00005017676
Gene Symbol: TLR8
3 Cross references
173 Possible Orthologues:

Toll Like Receptor 8

Ensembl ID : ENSOKIG00005029812
Gene Symbol: TLR8
3 Cross references
130 Possible Orthologues:

Toll-Like Receptor 2

Ensembl ID : ENSOKIG00005033444
Gene Symbol: LOC109882984
2 Cross references
213 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSOKIG00005010960
Gene Symbol: TAAR1
1 Cross references
146 Possible Orthologues:

Trace Amine Associated Receptor 1b

Ensembl ID : ENSOKIG00005010982
Gene Symbol: TAAR1B
1 Cross references
144 Possible Orthologues:

Transcription Factor P65

Ensembl ID : ENSOKIG00005029154
Gene Symbol: LOC109906578
3 Cross references
194 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSOKIG00005035830
Gene Symbol: TRPA1
3 Cross references
193 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1-Like

Ensembl ID : ENSOKIG00005026164
Gene Symbol: LOC109874702
3 Cross references
149 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1a

Ensembl ID : ENSOKIG00005025398
Gene Symbol: TRPA1A
1 Cross references
149 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).